Evidence map›Paper›PMID 32490123›Full record

ArticlePractical laboratory medicine2020

Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma.

Li Lei, Bradley A Stohr, Stacey Berry, Christina M Lockwood, Jessica L Davis, Erin R Rudzinski, Christian A Kunder

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Practical laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Progress Update in Pediatric Renal Tumors.Current oncology reports · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Li LeiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Bradley A StohrDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA.
Stacey BerryDepartment of Pathology, Cook Children's Medical Center, Fort Worth, TX, USA.
Christina M LockwoodDepartment of Laboratory Medicine, University of Washington, Seattle, WA, USA.
Jessica L DavisDepartment of Pathology, Oregon Health & Science University, Portland, OR, USA.
Erin R RudzinskiDepartment of Laboratories, Seattle Children's Hospital, Seattle, WA, USA.
Christian A KunderDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo identify oncogenic driver mutations in congenital mesoblastic nephroma (CMN) cases lacking

designThe institutional pathology database was queried for cases with a morphologic diagnosis of CMN. Cases positive for

resultsThree of four internal cases harbor an

conclusionsEGFR activation, predominantly via

Indexed as

CCSK, clear cell sarcoma of the kidneyCMN, congenital mesoblastic nephromaCongenital mesoblastic nephromaEGFR, kinase domain duplicationETV6-NTRK3FISH, fluorescence in situ hybridizationIFS, infantile fibrosarcomaITD, internal tandem duplicationKDD, kinase domain duplicationNGS, next-generation sequencing

Identifiers

PMID32490123
PMCPMC7260589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.